EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer ; volume:9 ; number:1 ; day:22 ; month:7 ; year:2016 ; pages:1-5 ; date:12.2016
Journal of hematology & oncology ; 9, Heft 1 (22.7.2016), 1-5, 12.2016
- Creator
-
Wang, Shuhang
- Contributor
-
Tsui, Stella T.
Liu, Christina
Song, Yongping
Liu, Delong
SpringerLink (Online service)
- DOI
-
10.1186/s13045-016-0290-1
- URN
-
urn:nbn:de:1111-201607256269
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wang, Shuhang
- Tsui, Stella T.
- Liu, Christina
- Song, Yongping
- Liu, Delong
- SpringerLink (Online service)
Other Objects (12)
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Third-generation prospect theory
Third-generation prospect theory
Third-generation femtosecond technology
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Third‐Generation Sequencing of Epigenetic DNA
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Third-generation prospect theory
Third-generation prospect theory
Third-generation femtosecond technology
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Third‐Generation Sequencing of Epigenetic DNA
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Third-generation prospect theory
Third-generation prospect theory
Third-generation femtosecond technology
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines